EZH2 and nasopharyngeal carcinoma: Interestingly, EED226 could also potently inhibit the activity of PRC2 containing a mutant EZH2 protein resistant to SAM-competitive inhibitors.428 A phase I trial (NCT02900651) is ongoing to evaluate the safety and efficacy of EED226 in patients with advanced malignancies, such as DLBCL, nasopharyngeal carcinoma (NPC) or other advanced solid tumors for whom no further effective standard treatment is available.